US FDA’s Career Leaders Quietly Emerge As Effective Operators In COVID-19 Response
Executive Summary
FDA medical review leaders have been remarkable on balancing the two challenges of finding treatments for COVID-19 and keeping everything else running on time.
You may also be interested in...
President ????: What US Election Uncertainty Means For Biopharma
Worst case scenario is civil unrest that might disrupt clinical trials and manufacturing. Under a more moderate scenario, companies must delay business planning because the US policy environment remains cloudy.
President ????: What US Election Uncertainty Means For Biopharma
Worst case scenario is civil unrest that might disrupt clinical trials and manufacturing. Under a more moderate scenario, companies must delay business planning because the US policy environment remains cloudy.
Informed Consent: For COVID-Affected Studies, A Handwritten Document May Suffice
Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol and texting or emailing a photo of the signed document to the investigator, US FDA says in latest guidance update.